10x Genomics (TXG) vs Waters (WAT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
10x Genomics (TXG) has outperformed Waters (WAT) over the past year, gaining 556.0% versus a gain of 37.0%. Over five years, WAT leads with a +26.5% price change compared with -50.0% for TXG. Waters is the larger company by market cap ($41.90 billion vs $9.77 billion), about 4.3 times the size.
On valuation, Waters trades at a lower forward P/E (25.8x vs 977.8x for 10x Genomics). Waters converts more of its revenue into profit, with a net margin of 20.3% versus -6.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TXG | WAT |
|---|---|---|
| Share price | $74.97 | $426.73 |
| Market cap | $9.77B | $41.90B |
| 1-day change | -1.49% | -2.12% |
| YTD return | +366.58% | +14.79% |
| 1-year return | +556.03% | +36.95% |
| 5-year return | -50.02% | +26.48% |
| P/E ratio (TTM) | — | 108.03 |
| Forward P/E | 977.76 | 25.80 |
| EPS (TTM) | $-0.59 | $3.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $642.82M | $3.17B |
| Revenue growth (YoY) | +5.25% | +6.99% |
| Net income (latest FY) | $-43.54M | $642.63M |
| Gross margin | 69.05% | 59.28% |
| Operating margin | -9.49% | 25.36% |
| Net margin | -6.77% | 20.30% |
| 52-week high | $102.81 | $454.54 |
| 52-week low | $11.16 | $282.77 |
| Distance from 52-week high | -27.08% | -6.12% |
| Analyst consensus | buy | buy |
| Avg. price target upside | -11.96% | +6.22% |
| Average volume | 3.25M | 769.63K |
| Shares outstanding | 120.21M | 98.19M |
| Employees | 1,178 | 16,000 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Waters is about 4.3 times larger than 10x Genomics by market value ($41.90B vs $9.77B).
- TXG has outperformed WAT by 519.1 percentage points over the past year.
- Waters is more profitable, keeping 20.3 cents of every revenue dollar as net income versus -6.8 cents for 10x Genomics.
About 10x Genomics
TXG stock →10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.
Industrials · Biotechnology: Laboratory Analytical Instruments · 1,178 employees
About Waters
WAT stock →Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA.
Industrials · Biotechnology: Laboratory Analytical Instruments · 16,000 employees
TXG vs WAT FAQ
Which is bigger, 10x Genomics or Waters?
Waters (WAT) is larger, with a market capitalization of $41.90B compared with $9.77B for 10x Genomics (TXG).
Which stock has performed better over the past year, TXG or WAT?
TXG returned +556.03% over the past 12 months, compared with +36.95% for WAT (price return, excluding dividends). Past performance does not predict future results.
Are 10x Genomics and Waters in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.